MannKind Corp
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,422.70 | 29.40 | 0.31% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,635.24 | 124.14 | 0.49% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 65,538.17 | 318.26 | -0.48% |
| NZX 50 Index | 14,029.48 | 36.76 | 0.26% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,214.50 | 30.80 | 0.34% |
| SSE Composite Index | 3,889.24 | 0.20 | -0.01% |